DOCSLIB.ORG

Appendix 1. MRC Centre Principal Investigators 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Appendix 1. MRC Centre Principal Investigators 2016 Director Professor Michael Hanna Co-directors London Professor Mary M. Reilly Professor Francesco Muntoni Co-directors Newcastle Professor Kate Bushby Professor Doug Turnbull London Dr Chris Clark Professor Giulio Cossu Professor Michael Duchen Professor Elizabeth Fisher Professor Xavier Golay Professor Linda Greensmith Professor John Hardy Professor Henry Houlden Professor Kristjan Jessen Professor Dimitri Kullmann Professor Martin Koltzenburg Dr Michael Lunn Professor Paul Matthews Professor Jennifer Morgan Dr Gita Ramdharry Professor Gipi Schiavo Dr Stephanie Schorge Dr John Thornton Professor Thomas Voit Professor Paul Whiting (as of Oct 2016) Professor Tarek Yousry Newcastle Professor Andrew Blamire Dr Grainne Gorman Professor Rita Horvath Dr Kieren Hollingsworth Professor Hanns Lochmüller Dr Robert McFarland Dr James Miller Professor Avan Aihie Sayer (as of Aug 2016) Professor Volker Straub Professor Robert Taylor Professor Michael Trenell Cambridge Professor Patrick Chinnery Senior Team Professor Michael Hanna I am interested in how molecular genetic and pathophysiological knowledge can translate into precision diagnostics and treatments in neuromuscular diseases. I established and funded collaborative interdisciplinary clinical, genetic and cellular research programmes in channelopathies, mitochondrial disease and degenerative myopathies that have progressed molecular understanding, resulted in new diagnostic tests and improved patient outcomes in experimental trials. My channel research has translated into the UK national NHS highly specialist clinical service and diagnostic reference laboratory and was selected as a REF 2014 UCL impact case. I am interested in tackling the “translational gap” between discovery and patient benefitThe MRC Centre links UCL and Newcastle universities and provides a national experimental medicine platform. Our translational impact includes stratified patient cohorts >10,000 patients, 99 natural history studies and experimental trials completed, 8000 human cell lines in MRC biobank, 24 clinical and non-clinical PhD students graduated, new MRI biomarkers for NMD adopted internationally, >1000 publications across all PIs, European Medicines Agency orphan drug status & recent, 2015, FDA licensing based on MRC Centre trials. Added value of being an MRC Centre PI My research has benefitted enormously from the MRC Centre. The support from the trial coordinators has been crucial for the development of patient cohorts, the natural history studies and the clinical trials. Access to the state of the art biobank facilities has facilitated pathogenetic and pre-clinical studies in channelopathies and IBM. The MRI biomarker development in UCL has allowed us to develop a biomarker which is responsive over 1 year in IBM which will be revolutionary in future clinical trials. The training programme of the centre has allowed us to recruit excellent clinical and non-clinical PhD students who have contributed to may of my studies in channelopathy, mitochondrial diseases and IBM. Professor Mary M. Reilly 2 | P a g e I have a long standing research interest in the inherited neuropathies with an emphasis on translational research. A major part of our current programme is gene identification (e.g. NEFH, BICD2, MARS, FBOX38) and functional analysis of identified genes (e.g. BICD2, FBOX38 and IGHMPB2). My more clinically focused translational research incudes detailed natural history studies in many inherited neuropathies (CMT, HNPP, HMN, HSN, TTR-FAP) with the aim of being trial ready as well as understanding the disease pathogenesis and evolution better, developing new outcomes measures (e.g. CMT neuropathy score for CMT) and new disease biomarkers for disease progression (e.g. MRI neuromuscular protocol for CMT1A). I was the UK PI for the first international UK-Italian trial in CMT1A and currently am conducting a pre-clinical trial outcome measure identification study in HSN1 in preparation for a clinical trial of serine in HSN1 based on work of our group and others in the pathogenesis of this condition and an aerobic exercise trial in CMT1A. Added value of being an MRC Centre PI My group has had major benefit from the MRC Centre. The support from the experimental medicine trial coordinators has allowed us to setup and develop the MRC Centre inherited neuropathy stratified cohort which currently has 3668 patients entered. The use of this cohort and also fibroblasts from the MRC Centre biobank has been instrumental in helping both new gene discovery and functional studies in these new genes. The experimental medicine trial coordinators have also helped the setting up of and the coordination of the ongoing aerobic exercise study in CMT. The MRI biomarker development in UCL has allowed us to develop a biomarker which is responsive over 1 year in CMT1A which will be revolutionary in future clinical trials. The training programme of the centre has allowed us to recruit excellent clinical and non-clinical PhD students who are the first authors in many of our studies and publication. Professor Francesco Muntoni I am a paediatric neurologist clinician scientists interested in clinical and molecular aspects of paediatric neuromuscular disorders, and responsible for a national clinical and diagnostic service for rare congenital muscle diseases. I have been co-director of the MRC Centre since its inception. Regarding my research interests, I am actively involved in the deep phenotyping of children with neuromuscular diseases which led to the identification of more than 30 neuromuscular disease genes, 8 of which by my group. I have pursued functional characterisation of some of these genes by relevant knock-in or knock down animal models. I have a strong translational research interest in Duchenne muscular dystrophy (DMD) and spinal muscular atrophy. I am the Principal Clinical Investigator of an UK Consortium established a decade ago to pursue genetic therapies for Duchenne muscular dystrophy (DMD), and spinal muscular atrophy (SMA) using splice switching antisense oligonucleotides. I performed 3 investigator led clinical trials to induce exon skipping in DMD using antisense oligonucleotides (targeting exon 51, and exon 53 using a morpholino chemistry, see http://www.skip-nmd.eu/). Added value of being an MRC Centre PI The MRC Centre allows me to: i. have study coordinators support for the clinical trials and natural history studies currently underway in the Dubowitz Neuromuscular Centre (more than 20 at the moment); ii. access state of the art biobank facilities to assess the identification of novel targets for 3 | P a g e antisense oligonucleotides and other approaches relevant for a variety of neuromuscular diseases; iii. develop novel non-invasive muscle imaging; iv. access animal facilities for testing efficacy of novel therapeutic approaches; v. Train the next generation of clinician scientists with expertise in experimental trials in children Professor Kate Bushby Kate Bushby is a clinical academic with joint appointments between the John Walton Muscular Dystrophy Research Centre at Newcastle University and the NHS. She is a member of the Neuromuscular Research Group within the Institute of Genetic Medicine at Newcastle University and plays a leading role in the National Commissioning Group (NCG) for rare neuromuscular diseases. Along with Volker Straub, Professor Bushby was one of the founding coordinators the TREAT-NMD network for accelerating therapy development in neuromuscular diseases. She now plays a leading role in the European and national rare disease policy areas, and is acting as an invited expert on the new Commission expert group on rare diseases. In addition to this, she has overall responsibility for activities relating to the impact of FP7 project RD-Connect on the broader rare disease field. Professor Bushby has a longstanding interest in the molecular genetics of the limb-girdle muscular dystrophies and related disorders and is interested in the best possible development and implementation of care guidelines as well as clinical trials. Her team has developed an extensive programme of research in NMD from basic molecular pathology to clinical studies. Added value of being an MRC Centre PI My research has benefitted in multiple ways from the MRC Centre. The support from the trial coordinators, the access to a biobank and the PhD students have all contributed to my research in muscular dystrophies. The interaction between PIs in Newcastle and UCL through the MRC centre has had major benefits to the Newcastle Neuromuscular disease research programme. Professor Sir Doug Turnbull Professor Sir Doug Turnbull is Director and PI of the MRC/BBSRC Centre for Ageing and Vitality focused on mechanisms of ageing and how these are modified by lifestyle interventions. The MRC/BBSRC Centre was renewed in 2013 and predominantly explores the role of mitochondria in 4 | P a g e ageing and age related disease. Professor Turnbull is also Director of the Wellcome Trust Centre for Mitochondrial Research, which has had a major impact on mitochondrial disease over the last four years. Professor Turnbull also had a major role in changing the law to allow mitochondrial donation in the UK, working closely with policy makers and patients. Professor Turnbull led the commissioning of a new and unique NHS service for patients with mitochondrial disease – the NHS Highly Specialised Service for Rare Mitochondrial Diseases of Adults and Children. Coordinating activity across
Recommended publications
  • Deficiency of the Zinc Finger Protein ZFP106 Causes Motor and Sensory

    Deficiency of the Zinc Finger Protein ZFP106 Causes Motor and Sensory

    Human Molecular Genetics, 2016, Vol. 25, No. 2 291–307 doi: 10.1093/hmg/ddv471 Advance Access Publication Date: 24 November 2015 Original Article ORIGINAL ARTICLE Deficiency of the zinc finger protein ZFP106 causes Downloaded from https://academic.oup.com/hmg/article/25/2/291/2384594 by guest on 23 September 2021 motor and sensory neurodegeneration Peter I. Joyce1, Pietro Fratta2,†, Allison S. Landman1,†, Philip Mcgoldrick2,†, Henning Wackerhage3, Michael Groves2, Bharani Shiva Busam3, Jorge Galino4, Silvia Corrochano1, Olga A. Beskina2, Christopher Esapa1, Edward Ryder4, Sarah Carter1, Michelle Stewart1, Gemma Codner1, Helen Hilton1, Lydia Teboul1, Jennifer Tucker1, Arimantas Lionikas3, Jeanne Estabel5, Ramiro Ramirez-Solis5, Jacqueline K. White5, Sebastian Brandner2, Vincent Plagnol6, David L. H. Bennet4,AndreyY.Abramov2,LindaGreensmith2,*, Elizabeth M. C. Fisher2,* and Abraham Acevedo-Arozena1,* 1MRC Mammalian Genetics Unit, Harwell, Oxfordshire OX11 0RD, UK, 2UCL Institute of Neurology and MRC Centre for Neuromuscular Disease, Queen Square, London WC1N 3BG, UK, 3Health Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK, 4Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK, 5Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK and 6UCL Genetics Institute, London WC1E 6BT, UK *To whom correspondence should be addressed. Email: [email protected] (A.A.)/e.fi[email protected] (E.M.C.F.)/[email protected] (L.G.) Abstract Zinc finger motifs are distributed amongst many eukaryotic protein families, directing nucleic acid–protein and protein–protein interactions. Zinc finger protein 106 (ZFP106) has previously been associated with roles in immune response, muscle differentiation, testes development and DNA damage, although little is known about its specific function.
  • EMJ-5.2-2020-4.Pdf

    EMJ-5.2-2020-4.Pdf

    Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al.
  • Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation

    Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation

    CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984).
  • Wellcome Four Year Phd Programme in Integrative Cell Mechanisms

    Wellcome Four Year Phd Programme in Integrative Cell Mechanisms

    2021 Wellcome Four Year PhD Programme in Integrative Cell Mechanisms Training the next generation of Molecular Cell Biologists Background and Aims of Programme The Wellcome Four Year PhD Programme in Integrative Cell Mechanisms (iCM) is closely associated with the Wellcome Centre for Cell Biology and trains the next generation of cell and molecular biologists in the application of quantitative methods to understand the inner workings of distinct cell types in different settings. A detailed understanding of normal cellular function is required to investigate the molecular cause of disease and design future treatments. However, data generated by biological research requires increasingly complex analysis with technological advances in sequencing, mass spectrometry/proteomics, super-resolution microscopy, Wellcome Centre for Cell Biology 2021 synthetic and structural biology generating increasingly large, complex datasets. In addition, innovations in computer sciences and informatics are transforming data acquisition and analysis and breakthroughs in physics, chemistry and engineering allow the development of devices, molecules and instruments that drive the biological data revolution. Exploiting technological advances to transform our understanding of cellular mechanisms will require scientists who have been trained across the distinct disciplines of natural sciences, engineering, informatics and mathematics. To address this training need, iCM PhD projects are cross-disciplinary involving two primary supervisors with complementary expertise. Supervisor partnerships pair quantitative scientists with cell biologists ensuring that students develop pioneering cross-disciplinary collaborative projects to uncover cellular mechanisms relevant to health and disease. We aim to recruit students with a variety of backgrounds across the biological and physical sciences, including Biochemistry, Biomedical Science, Cell Biology, Chemistry, Computational Data Sciences, Engineering, Genetics, Mathematics, Molecular Biology and Physics.
  • Cell Type-Specific Long-Term Plasticity at Glutamatergic Synapses Onto Hippocampal Interneurons Expressing Either

    Cell Type-Specific Long-Term Plasticity at Glutamatergic Synapses Onto Hippocampal Interneurons Expressing Either

    The Journal of Neuroscience, January 27, 2010 • 30(4):1337–1347 • 1337 Behavioral/Systems/Cognitive Cell Type-Specific Long-Term Plasticity at Glutamatergic Synapses onto Hippocampal Interneurons Expressing either Parvalbumin or CB1 Cannabinoid Receptor Wiebke Nissen,1 Andras Szabo,1 Jozsef Somogyi,2 Peter Somogyi,2 and Karri P. Lamsa1 1Department of Pharmacology, Oxford University, Oxford OX1 3QT, United Kingdom, and 2Medical Research Council Anatomical Neuropharmacology Unit, Oxford University, Oxford OX1 3TH, United Kingdom Different GABAergic interneuron types have specific roles in hippocampal function, and anatomical as well as physiological features vary greatly between interneuron classes. Long-term plasticity of interneurons has mostly been studied in unidentified GABAergic cells and is known to be very heterogeneous. Here we tested whether cell type-specific plasticity properties in distinct GABAergic interneuron types might underlie this heterogeneity. We show that long-term potentiation (LTP) and depression (LTD), two common forms of synaptic plasticity, are expressed in a highly cell type-specific manner at glutamatergic synapses onto hippocampal GABAergic neurons. Both LTP and LTD are generated in interneurons expressing parvalbumin (PVϩ), whereas interneurons with similar axon distributions but expressing cannabinoid receptor-1 show no lasting plasticity in response to the same protocol. In addition, LTP or LTD occurs in PVϩ interneurons with different efferent target domains. Perisomatic-targeting PVϩ basket and axo-axonic interneurons express LTP, whereas glutamatergic synapses onto PVϩ bistratified cells display LTD. Both LTP and LTD are pathway specific, independent of NMDA receptors, and occur at synapses with calcium-permeable (CP) AMPA receptors. Plasticity in interneurons with CP-AMPA receptors strongly modulates disynaptic GABAergic transmission onto CA1 pyramidal cells.
  • Abstracts of Papers Presented at the Tenth Mammalian Genetics And

    Abstracts of Papers Presented at the Tenth Mammalian Genetics And

    Genet. Res., Camb. (2000), 76, pp. 199–214. Printed in the United Kingdom # 2000 Cambridge University Press 199 Abstracts of papers presented at the tenth Mammalian Genetics and Deelopment Workshop (Incorporating the Promega Young Geneticists’ Meeting) held at the Institute of Child Health, Uniersity College London on 17–19Noember 1999 " # Edited by: ANDREW J. COPP AND ELIZABETH M. C. FISHER 1Institute of Child Health, Uniersity College London, 30 Guilford Street, London WC1N 1EH, UK # Neurogenetics Unit, Imperial College School of Medicine, St Mary’s Hospital, Norfolk Place, London W2 1PG, UK Sponsored by: The Genetical Society, Promega (UK) Ltd and B&K Universal Group Ltd Evidence for imprinting in type 2 diabetes: detection of Identification of a locus for primary ciliary dyskinesia parent-of-origin effects at the insulin gene on chromosome 19 " " " STEWART HUXTABLE, PHILIP SAKER, LEMA S. L. SPIDEN , M. MEEKS , A. J. WALNE ,H. # # HADDAD, ANDREW HATTERSLEY, MARK BLAU , H. MUSSAFFI-GEORGY ,H. $ % % WALKER and MARK McCARTHY SIMPSON , M. EL FEHAID , M. CHEEBAB ,M. % % Section of Endocrinology, Imperial College School of AL-DABBAGH , H. D. HAMMUM ,R.M. " " Medicine, St Mary’s Hospital, London, UK GARDINER , E. M. K. CHUNG and H. M. " MITCHISON " Variation at the insulin gene (INS) VNTR is impli- Department of Paediatrics, Royal Free and Uniersity cated in type 1 diabetes, polycystic ovarian syndrome College Medical School, Uniersity College London, # and birthweight. Case-control studies inconsistently UK; Schneider Children’s Medical Center of Israel, $ show class III VNTR association with type 2 diabetes, Petech Tika, Israel; School of Medical Sciences, but may result from population stratification.
  • Floreat Domus 2011

    Floreat Domus 2011

    ISSUE NO.17 april 2011 Floreat Domus BALLIOL COLLEGE NEWS Special Feature: More than money Three Balliol Old Members talk about aid work People-powered politics Master on the move Stop Press: Election of New Master Balliol College is very pleased to announce that it has offered Contents the Mastership of the College Welcome to the 2011 to Professor Sir Drummond Bone (1968), MA DLitt DUniv edition of Floreat Domus. (Glas) FRSE FRSA, and he has accepted. The formal election will be in Trinity Term. contents page 28 Putting Margate Professor Bone will take up the back on the map post this October. For more page 1 College news The new Turner Contemporary information, go to www.balliol. page 6 Women at Balliol gallery, involving three Old Members ox.ac.uk/news/2011/march/ election-of-new-master page 8 College success page 30 In the dark without page 9 Student news nuclear power? Roger Cashmore and David Lucas page 10 Student success discuss the future of nuclear power Special feature Page 20–23 Page 39 A map of the heart page 12 page 32 Great adventurers 50th anniversary of Denis Noble’s The amazing trips made by Sir ground-breaking paper Adam Roberts and Anthony Smith Talking science page 13 page 33 Bookshelf in the centre of Oxford A selection of books published page 14 The Oxford by Balliol Old Members Student Consultancy page 34 Master on the move: page 15 The Oxford conversations around the world Microfinance Initiative Andrew and Peggotty Graham talk about their round-the-world trip Features Development news page 16 People-powered politics
  • A Case Study of Glaxosmithkline Plc )

    A Case Study of Glaxosmithkline Plc )

    )l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal.
  • Drugs That Changed the World

    Drugs That Changed the World

    Drugs That Changed the World Drugs That Changed the World How Therapeutic Agents Shaped Our Lives Irwin W. Sherman CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2017 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed on acid-free paper Version Date: 20160922 International Standard Book Number-13: 978-1-4987-9649-1 (Hardback) This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal respon- sibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not neces- sarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies’ and device or material manufacturers’ printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book.
  • The Clinical and Genetic Heterogeneity of Paroxysmal Dyskinesias

    The Clinical and Genetic Heterogeneity of Paroxysmal Dyskinesias

    doi:10.1093/brain/awv310 BRAIN 2015: 138; 3567–3580 | 3567 The clinical and genetic heterogeneity of paroxysmal dyskinesias Alice R. Gardiner,1,2 Fatima Jaffer,1,2 Russell C. Dale,3 Robyn Labrum,4 Roberto Erro,5 Esther Meyer,6 Georgia Xiromerisiou,2,7 Maria Stamelou,5,8,9 Matthew Walker,10 Dimitri Kullmann,10 Tom Warner,2 Paul Jarman,5 Mike Hanna,1 Manju A. Kurian,6,11 Kailash P. Bhatia5,* and Henry Houlden1,2,4,* Downloaded from ÃThese authors contributed equally to this work. Paroxysmal dyskinesia can be subdivided into three clinical syndromes: paroxysmal kinesigenic dyskinesia or choreoathetosis, paroxysmal exercise-induced dyskinesia, and paroxysmal non-kinesigenic dyskinesia. Each subtype is associated with the known http://brain.oxfordjournals.org/ causative genes PRRT2, SLC2A1 and PNKD, respectively. Although separate screening studies have been carried out on each of the paroxysmal dyskinesia genes, to date there has been no large study across all genes in these disorders and little is known about the pathogenic mechanisms. We analysed all three genes (the whole coding regions of SLC2A1 and PRRT2 and exons one and two of PNKD) in a series of 145 families with paroxysmal dyskinesias as well as in a series of 53 patients with familial episodic ataxia and hemiplegic migraine to investigate the mutation frequency and type and the genetic and phenotypic spectrum. We examined the mRNA expression in brain regions to investigate how selective vulnerability could help explain the phenotypes and analysed the effect of mutations on patient-derived mRNA. Mutations in the PRRT2, SLC2A1 and PNKD genes were identified in 72 families in the entire study.
  • Blunted Endogenous Opioid Release Following an Oral Dexamphetamine Challenge in Abstinent Alcohol- Dependent Individuals

    Blunted Endogenous Opioid Release Following an Oral Dexamphetamine Challenge in Abstinent Alcohol- Dependent Individuals

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Turton, S., Myers, J. F. M., Mick, I., Colasanti, A., Venkataraman, A., Durant, C., ... Lingford-Hughes, A. (2018). Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol- dependent individuals. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0107-4 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1038/s41380-018-0107-4 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Nature Publishing Group at https://www.nature.com/articles/s41380-018-0107-4 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Molecular Psychiatry https://doi.org/10.1038/s41380-018-0107-4 ARTICLE Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals 1 1 1,2 3,4 1 1 Samuel Turton ● James FM Myers ● Inge Mick ● Alessandro Colasanti ● Ashwin Venkataraman ● Claire Durant ● 5 6 6 7 8,9 8,10 Adam Waldman ● Alan Brailsford ● Mark C Parkin ● Gemma Dawe ● Eugenii A Rabiner ● Roger N Gunn ● 11 1 1 Stafford L Lightman ● David J Nutt ● Anne Lingford-Hughes Received: 21 September 2017 / Revised: 9 May 2018 / Accepted: 14 May 2018 © The Author(s) 2018.
  • 260 Book Reviews

    260 Book Reviews

    Book Reviews relation to the development of neurology as a arguments of Kant or Goethe, or indeed medical specialty and to knowledge of the Alexander Bain, were not? brain. (This in part perhaps reflects the lack of This “life” will give great pleasure and archival material on Head’s scientific work.) interest to many readers, perhaps most of all In particular, Head’s career as a theorist draws to those who, like Head himself, find both on the work of John Hughlings Jackson, work the sciences and the arts personally which, so Head claimed, had been almost indispensable. totally ignored. Had it? What reception did Head’s theory of sensation have? The Roger Smith, biography does not enable us to judge Head’s Moscow originality. (For Jackson, one should turn, perhaps the message is, to Jacyna’s earlier fine study, Lost words: narratives of language and Roy Church and E M Tansey, Burroughs the brain, 2000.) Head’s functionalist way of Wellcome & Co.: knowledge, trust, profit thinking encouraged him to mix physiological and the transformation of the British and psychological languages and therapies. pharmaceutical industry, 1880–1940, How special was this? Secondly, the book Lancaster, Crucible Books, 2007, pp. xxvii, does look “outwards” from the archive, as 564, illus. £19.99, $39.99 (paperback 97801- opposed to using the archive to illuminate the 905472-07-9). man, in two regards. The first of these, naturally, is to use the individual career to This work, based on detailed research of the illustrate contemporary medical practice. In firm’s archives, aims to tell the history of addition, however, Jacyna proposes a large Burroughs Wellcome, founded by Silas thesis, which gives the book its title, that Burroughs and Henry Wellcome in 1880, Head’s manner of life and work makes him an which eventually became the largest British exemplary “modernist”.